DELAWARE, USA – 12 January 2026 – Omniscope, a leader in advanced molecular profiling technology, and Fox Chase Cancer Center, a National Cancer Institute-designated comprehensive cancer center, today announced a new research collaboration aimed at identifying novel biomarkers for immune checkpoint inhibitor (ICI) response in non-small cell lung cancer. This partnership will leverage Omniscope's proprietary T cell profiling platform to analyze patient samples from clinical studies at Fox Chase Cancer Center.
The collaboration will focus on a prospective study led by Fox Chase Cancer Center, "Immunotherapy induced T cell dynamics in non-small cell lung cancer." The research aims to explore T cell receptor (TCR) repertoire from both blood and tissue of patients undergoing ICI treatment. The primary objectives are to correlate baseline and dynamic T cell activity scores with clinical response and to predict therapeutic response and efficacy for patient treatment stratification using T cells as living biomarkers.
"This collaboration with Fox Chase Cancer Center represents a pivotal step in our mission to bring precision medicine to the forefront of cancer care," said Prof. Holger Heyn, Co-founder & CSO at Omniscope. "By applying our technology to analyze the T cell landscape in patients treated with immunotherapy, we aim to uncover immune biomarkers to predict who will respond to these life-saving treatments. We are excited to work with the world-leading team at Fox Chase Cancer Center to advance this unmet clinical need."
The partnership enables Omniscope to perform T cell signature profiling using its proprietary technologies on patient samples, including peripheral blood mononuclear cells and archival tumor tissue, provided by Fox Chase Cancer Center. This integration of clinical data and advanced molecular analysis is designed to rapidly accelerate biomarker discovery.
"The search for reliable biomarkers to guide immunotherapy decisions has been a major focus in oncology, and this study could provide a new dimension to our understanding," said Dr. Hossein Borghaei, DO, MS, Chief of Thoracic Medical Oncology and Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center. "By longitudinally tracking T cell clonotypes, we hope to identify a dynamic 'immunosignature' that goes beyond traditional static markers like PD-L1 and tumor mutation burden. This partnership with Omniscope brings a unique technological capability to our research, and we look forward to the insights it will generate for the scientific community and for future patient care."
The research is a non-therapeutic biosample and correlative investigation. The findings from this study will be shared with the broader scientific community, advancing efforts to stratify patients by immune profile to guide therapy selection, reduce unnecessary costs, and ultimately improve response rates, survival, and quality of life.
ABOUT OMNISCOPE:
Omniscope is a techbio company specializing in advanced immune profiling technologies. Its proprietary AI-enabled platforms enable deep, high-resolution analysis of immune cell dynamics, providing critical insights for personalized medicine, biomarker discovery, and the development of novel immunotherapies.
Please see: https://www.omniscope.ai/about-us
ABOUT FOX CHASE CANCER CENTER:
Fox Chase Cancer Center, a part of Temple Health, is a National Cancer Institute-designated Comprehensive Cancer Center, an elite status held by only 57 centers nationwide. Founded in Philadelphia in 1904, Fox Chase was one of the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. The mission of Fox Chase Cancer Center is to prevail over cancer by marshaling hearts and minds in bold scientific discovery, pioneering prevention, and compassionate care. Fox Chase is a leader in basic, translational, and clinical research, and its researchers have won the highest awards in their fields, including two Nobel Prizes. The Center's nursing program has received the Magnet recognition for excellence, and it is a member of the Alliance of Dedicated Cancer Centers.
